Last quarter (Q3 2025), MoonLake Immunotherapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, MoonLake Immunotherapeutics's net income was $-69.73M. See MoonLake Immunotherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00	$ 0.00	$ -4.97K	$ 0.00
Operating Expenses	$ 143.09M	$ 54.12M	$ 65.06M	$ 53.57M	$ 105.75K
Depreciation and Amortization	$ 1.38M	$ 370.32K	$ 164.78K	$ 4.97K	$ 0.00
EBITDA	$ -141.71M	$ -53.75M	$ -64.90M	$ -53.63M	$ -90.84K
Operating Income	$ -143.09M	$ -54.12M	$ -65.06M	$ -53.58M	$ -105.75K
Other Income/Expenses	$ 22.13M	$ 10.14M	$ 591.73K	$ -61.85K	$ 14.92K
Pretax Income	$ -120.96M	$ -43.98M	$ -64.47M	$ -53.64M	$ -90.84K
Net Income	$ -118.94M	$ -36.01M	$ -49.97M	$ -53.64M	$ -90.84K
Per Share Metrics
Basic EPS	$ -1.89	$ -0.73	$ -2.20	$ -1.45	$ -0.01
Diluted EPS	$ -1.89	$ -0.73	$ -2.20	$ -1.45	$ -0.01
Weighted Average Shares Outstanding	62.87M	49.12M	29.36M	36.93M	14.80M
Weighted Average Shares Outstanding (Diluted)	62.87M	49.12M	29.36M	36.93M	14.80M

Currency in USD

MoonLake Immunotherapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing